© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Flupirtine maleate stands as a drug that tells a story beyond most common analgesics. In the late 1970s, chemists in Germany were on the hunt for alternatives to opioids and NSAIDs, searching for something that would address pain without digging users into a pit of dependency or driving their stomach linings to revolt. They wanted a compound that dampened pain by targeting neuron activity differently. Through those early years, researchers worked through hundreds of chemical tweaks, chasing a molecule with an acceptable balance of effectiveness and safety. By the 1980s, flupirtine began showing up in European pharmacies as a prescription-only option for moderate to severe pain, mostly for musculoskeletal complaints. It earned lots of attention as a non-opioid analgesic acting through unique neurological pathways, especially in Germany, Austria, and a few other countries. More than four decades later, the story pivots: use restrictions swept in after reports of rare but serious liver toxicity, and debate continues among scientists whether its risks justify its rewards.
Flupirtine maleate comes as a crystalline powder, usually packed in moisture-tight containers to avoid clumping. Commercial products carry the active pharmaceutical ingredient alone or mixed into capsules and tablets. Doses typically land between 100 mg and 400 mg per intake, with instructions to avoid prolonged therapy unless under direct medical supervision. A lot of clinicians liked flupirtine because its mechanism spares patients from the constipation and sedation that hamper opioid therapy. The drug’s pain-targeting effects arise by opening potassium channels in neuron membranes and modulating NMDA receptors, two routes that don’t spark addiction the way opioids do. Thousands of prescriptions went out for post-surgical pain, nerve pain, and even fibromyalgia, though the markets shifted sharply since the EMA flagged its risks.
Anyone who’s handled the compound sees a white or pale yellow crystalline powder, with a sharp melting point between 207 and 212°C. Flupirtine maleate dissolves well in water and ethanol, less so in non-polar solvents such as hexane. Molecular formula C15H17FN4O2·C4H4O4 pushes the total weight just above 400 g/mol. The presence of fluorine gives it a fingerprint in spectroscopic identification, with characteristic absorption peaks showing up under IR and NMR analysis. Under normal storage—sealed, cool, and dry—the compound remains stable for at least a couple of years.
Pharmaceutical-grade flupirtine maleate must hit a minimum purity of 98%. Suppliers print extensive labeling to warn about possible liver complications, contraindications with alcohol, age usage limits, and mandatory blood monitoring during extended treatment. Standard analytical tests check the identity using melting point, IR, and HPLC profiles; impurity levels must not exceed thresholds set by regulatory bodies such as the EMA or FDA. Tablets and capsules receive extra labels: each batch documents the precise dose, manufacturer lot, expiry date, excipient list, and storage conditions. The documentation often carries black box warnings in the EU regions, reflecting stricter monitoring after the liver events came to light.
The typical synthetic process kicks off by combining ethyl 4-fluorobenzoylacetate and a substituted thiourea under reflux, pushing the two to condense and form the core pyridine-2,6-diamine structure. Chemists run extraction, purification, and then refinement steps to separate out flupirtine. After isolating a clean base, they react it with maleic acid to form the stable maleate salt—a step that improves bioavailability and shelf-life in final pills or powders. The entire process demands cautious temperature control, careful pH adjustment, and strict quality checks to keep impurities under the 2% mark. Each batch produces multi-kilogram yields, feeding into bulk tablet manufacture.
Flupirtine sits at an intersection of aromatic, heterocyclic, and amide chemistry. Structural tweaks by chemists over the years led to analogs designed for better safety or new indications, often by shifting the fluoro group or swapping the base for less hepatotoxic alternatives. The molecule stays relatively stable under mild acid or base, but high temperatures or strong oxidizers drive decomposition—a crucial detail during waste disposal and tablet production. One common research route: swap the maleate for citrate or tartrate salts, giving variations in solubility and absorption in the body. Every synthetic variant brings new hurdles in toxicity or metabolic fate, and so far, nothing in the flupirtine family fully matches the original for ease of manufacture and pain relief.
Over the years, flupirtine maleate’s passport has included dozens of names. Brand names often included Katadolon, Efurtin, Flupigal, and Metanor, which found shelves mostly in Germany, Russia, and parts of Eastern Europe. Generic supply runs under flupirtine, with the ‘maleate’ assigned for clarity when differentiating from base or other salts. Chemists tag it as ethyl 2-amino-6-[4-(4-fluorobenzyl)piperazin-1-yl]pyridine-3-carboxylate maleate in formal documentation. You spot synonyms floating through patents and research—SAE-14, D-9998—though regulators focus on the main compound’s safety, not its aliases.
Safety guidance has shifted as new data lands. Healthcare workers train to spot nausea, jaundice, and fatigue that signal potential liver issues. Guidelines urge doctors not to extend therapy beyond 14 days without a strong medical reason. In industrial settings, production staff must work under fume hoods, wear gloves, goggles, and chemical-resistant coats whenever handling the powder or solvents—exposure through skin or inhalation carries moderate risks. Waste handling facilities must keep track of unused flupirtine and offcuts, treating material as hazardous pharmaceutical waste. Regulatory agencies require companies to regularly update safety data sheets, review occupational exposure limits, and notify all downstream handlers of evolving health evidence.
Flupirtine made its biggest impact in neuropathic and musculoskeletal pain clinics, helping patients struggling after failed NSAID or weak opioid trials. Some neurologists turned to it for multiple sclerosis, headaches, or post-operative recovery. Pain specialists valued it for not triggering respiratory depression, a key concern among chronic pain patients with sleep apnea or lung issues. The remedy did not prove a universal fix. Regulatory restrictions now limit its use, but scientists continue probing unrelated neurological diseases where its potassium channel activity might play a role—such as in epilepsy, tinnitus, or rare movement disorders.
Research activity picked up in the late ’90s and early 2000s, driving publications on flupirtine’s unique mechanism—backed by imaging studies, rodent models, and small clinical trials. Laboratories modeled its potassium-channel opening using patch-clamp techniques, mapping how signals in pain pathways change after exposure. There’s a wave of effort given to figuring out if analogs could reduce the risk of liver injury by tweaking the thiourea group or building in metabolic “shunts” less likely to make toxic byproducts. Despite EMA restrictions, certain research teams push tandem projects with flupirtine relatives in hopes of developing painkillers that carry fewer liabilities. Every clinical trial must now build liver monitoring into its safety protocol, making progress slow but measured.
Liver warnings first started as isolated incidents, but a pattern emerged over thousands of patient-years. Hepatotoxicity took center stage, with patients sometimes breaking out in jaundice or liver enzyme elevations after a few weeks of therapy. Some cases advanced to severe liver failure, especially in those with pre-existing liver issues or concurrent use of alcohol or other drugs. Toxicologists chase the details, tracing how metabolic breakdown products—particularly certain reactive intermediates—build up in liver tissue and spark oxidative damage. Case reports forced regulators to demand ongoing liver function monitoring every two weeks for anyone on flupirtine, which led many doctors to switch to alternatives unless nothing else worked. Researchers continue studying animal models, trying liver-protective co-medications, but so far, no surefire workaround has cracked the mechanism of this toxicity.
The outlook for flupirtine stands at a crossroads, shaped by the ongoing need for non-addictive painkillers and the tough reality of its risk profile. Pain medicine as a field keeps hunting for alternatives that don’t carry the chains of opioid addiction or NSAID-induced stomach ulcers. Interest in flupirtine hasn’t vanished—chemists and pharmacologists push forward with analogs meant to sidestep its metabolic bottlenecks and explorers in neuroscience keep finding new targets for similar drugs regardless of current regulatory red tape. Patient groups continue pushing for research funds to support next-generation compounds, hoping the balance of pain relief versus long-term health can tilt in their favor. The challenge remains: finding a sweet spot between meaningful relief and manageable risk—a goal that keeps flupirtine maleate, with all its hard lessons, relevant in the ongoing story of pain therapy.
People living with chronic pain often shuffle between medications, hoping for a solution that doesn’t leave them with blunt side effects or little relief. Flupirtine Maleate entered the conversation as an option for pain that doesn’t fit neatly into the typical categories we hear about—tough pain that traditional medicines often miss. It’s not your standard painkiller either. Unlike codeine or paracetamol, flupirtine draws on a unique way of working in the body. It interacts with neurons, helping to control how pain messages travel through the nervous system, particularly in cases where other treatments aren’t cutting it.
Flupirtine isn’t an opioid. Doctors appreciated that quality, especially with the crisis around opioid misuse sweeping across the globe. Flupirtine doesn’t suppress breathing or induce the same risk of addiction, which made it a hopeful answer for long-term pain patients. It targets nerve-related pain, like that from damaged nerves or muscle spasms—the kinds where over-the-counter medication barely scratches the surface. People with conditions such as fibromyalgia, neuropathic pain, and migraines began to find reasons to ask about it in clinics.
The down-to-earth truth about medicine always reveals itself after years in circulation. As people started using flupirtine more regularly, especially in Europe, questions about its safety bubbled up. Specialists noticed that some patients developed serious liver problems—sometimes after only a short course. The cases weren’t isolated, making it impossible for regulators to shrug off these risks. In several countries, doctors stopped prescribing it. European regulators, after reviewing the evidence, saw the risk as outweighing the benefits, especially with frequent or prolonged use. This reality shut down most discussions about flupirtine as a long-term solution. Instead, it highlighted the ongoing struggle to balance pain relief with safety.
As someone who has worked closely with chronic pain patients and pharmacists struggling to weigh the risks and benefits of various medications, the flupirtine story stands out. Most patients just want their lives back—pain shouldn’t steal their independence. It’s tough seeing hope in a new drug only to find out about unforeseen dangers months or years later. With flupirtine, the excitement quickly gave way to caution. Health authorities recommended that doctors run regular liver checks, and urged patients to watch for symptoms like yellowing skin or dark urine. Patients faced yet another round of tough choices—trade pain for potential organ damage, or stick with medicines that only half-work.
The experience with flupirtine pushes both research and policy to keep searching for safe pain management tools. Regular drug monitoring, clearer patient information, and shared decision-making aren’t just buzzwords—they’re needed here. Scientists and regulators continue to work on medicines that relieve pain without such heavy costs. Pain relief has to be more than a tradeoff, and learning from flupirtine creates momentum to do better for patients in the future.
Many painkillers can bring relief, but every pill comes with risks. Flupirtine Maleate gained a reputation for easing moderate to strong pain, especially when folks couldn’t take opioids or nonsteroidal anti-inflammatory drugs. Still, every story with pain relief also comes with stories from people who felt side effects—sometimes mild, sometimes serious, sometimes reasons enough for doctors and regulators to take a second look. In medical practice and from conversations I’ve had with pharmacists, the effects often fall into two camps: what most people notice, and what should get everyone’s attention.
Drowsiness shows up in most people who use Flupirtine. The brain slows down, making focus tough. Some patients compare the feeling to a rough night’s sleep or a brain fog that won’t clear. Dizziness often follows, especially if someone stands up too quickly or tries to drive. Fatigue also lingers. Nurses warn patients about it: you’ll feel a heaviness, not just tiredness after a long day, but a sluggish feeling that can ruin plans.
Stomach upset, nausea, and dry mouth show up in lots of stories about this drug. I’ve noticed these complaints echoed again and again during rounds. They’re not dramatic, but they wear people down, sometimes making it harder to stick to pain management plans. Constipation and mild abdominal cramps can push folks to rethink if the benefits outweigh these daily annoyances.
A small group of people can break out in rashes, itchy skin, or swelling. Hives or sudden trouble breathing demand quick action. Rare, but every prescriber should warn their patient to call at the first sign. It pays to know what’s an emergency, not just a question for a future appointment.
For years, European health authorities raised alarms after seeing several reports of severe liver injury tied to Flupirtine. Jaundice (yellowing skin or eyes), dark urine, persistent nausea, or pain in the upper right abdomen should never get ignored. Blood tests to check liver health become mandatory if someone stays on the drug. Missing early warning signs has led to liver failure, hospitalization, and, tragically, death in a few cases. By 2018, the European Medicines Agency withdrew the approval for this medication, driven by mounting evidence of liver harm even from short courses at modest doses.
The only way to stay safe with Flupirtine is through partnership—regular check-ins, blood monitoring, and prompt reporting of symptoms. Pharmacists stress avoiding alcohol, checking labels for other drugs that tax the liver, and never doubling up on doses. No one should start Flupirtine without understanding why it’s prescribed, what side effects can happen, and what symptoms require a call or a visit right away.
If pain management demands Flupirtine, using the lowest dose and for the shortest possible time makes sense. Open conversation helps—patients who understand the real risks stand a better chance of getting the relief they need without walking blindly into bigger health problems. Talking with a trusted clinician before starting, asking honest questions, and sharing new symptoms make a difference that no warning label can match.
Flupirtine maleate has been around as a non-opioid pain reliever for chronic pain and muscle spasms. Many people welcomed it as an alternative to stronger painkillers and the side effects that often tag along with those medications. It’s not an opioid. It doesn’t put users at risk of addiction in the same way, which led plenty of doctors to write the prescription, especially in places trying to cut back on opioids.
Start looking deeper, though, and stories around flupirtine change. Reports from Europe and India flagged serious risks related to liver health. To put it plainly, using flupirtine over months or years brought a risk of liver damage that most people never saw coming. A 2013 review by the European Medicines Agency pointed out enough cases of severe hepatitis and even liver failure that they decided to pull the drug for anything more than short-term relief. If a medication works for pain but can cause permanent liver injury, trust erodes quickly.
I’ve watched a friend struggle through chronic back pain, tried every kind of pill, and for a while, flupirtine seemed like a blessing. Over six months, though, their regular blood tests started showing liver numbers moving in a bad direction. Their doctor picked up on it before it got out of hand. Many people taking medicine for pain don’t get regular, thorough liver tests, or push through discomfort without realizing a new problem is brewing. A few missed signs or skipped appointments, and things spiral out of control. When your daily routine involves popping a pill, long-term safety isn’t theoretical. It hits home fast if lab results or symptoms go south.
Multiple studies confirm the link between flupirtine and liver injury. Back when it was more commonly prescribed, clinicians started seeing a pattern—hepatitis, jaundice, and even cases needing transplants. The European regulator estimated that up to 1 in every 10,000 people who used the drug could develop severe problems. For rare side effects, that’s worrisome, especially since testing can’t always predict in advance who ends up affected. Guidelines started urging doctors to keep patients on flupirtine only if other treatments failed and to monitor liver enzymes regularly. The cautious approach is there for a reason.
Anyone asking about flupirtine for their own health deserves honesty and clear guidance. Regular check-ups and blood tests are not enough to cancel out the risk. More countries chose to ban or restrict the drug. Safer alternatives, with track records built around fewer life-threatening issues, offer better peace of mind for people with chronic pain. Pain management needs more than a quick fix or a different pill. Navigating options with a healthcare professional and weighing personal risk factors beats waiting for liver damage to announce its presence. Flupirtine’s story reminds us: no painkiller can fix everything, and side effects change the landscape far more than most labels admit.
Doctors sometimes choose Flupirtine Maleate to manage pain when common drugs like acetaminophen or opioids either don’t cut it or bring too many side effects. People want fast pain relief, but sometimes the risks of a drug deserve stronger attention than the benefits. Flupirtine doesn’t belong on every prescription pad. I’ve seen it prescribed, watched pharmacists hesitate, and heard patients ask why some regions pulled it off shelves. Fact is, we have to talk openly about the downsides, not hide behind plain package inserts.
Those who already deal with liver disease or have spiked liver enzyme levels face a real threat from Flupirtine. In Europe, rising reports of serious, sometimes irreversible liver damage pushed the European Medicines Agency to restrict Flupirtine’s use, and the drug isn’t even available in some countries anymore. Studies link the drug to both acute liver failure and chronic hepatitis, sometimes after short courses. Doctors run regular liver tests with Flupirtine, but even then, things can go wrong between appointments. Instead of tossing out these risks because they sound rare, anyone with a history of liver problems should avoid this drug completely.
Pregnant and breastfeeding women shouldn’t touch Flupirtine, since no good data exists to guarantee safety for a developing baby or infant. Every drug crosses the placenta to some extent, and unknowns only add anxiety. Pediatric use isn’t recommended either, as safety hasn’t been proven and kids tend to react unpredictably to drugs meant for adults. I can’t count the times families have asked if there’s a “safe dose” for their child—truth is, for Flupirtine, there isn’t one we can promise won’t harm.
People already taking other drugs that challenge the liver—like certain anti-epileptics or tuberculosis medications—should avoid Flupirtine. There’s no safe way to balance two drugs that both hit liver cells. Flupirtine also acts on neurotransmitters, so mixing it with muscle relaxants, sleep aids, or antipsychotics could boost drowsiness or confusion. I’ve seen older adults, especially, lose balance or develop new memory gaps from combinations the prescriber overlooked. Those with chronic neurological problems, including myasthenia gravis, land on the no-go list for similar reasons—the risk of worsening muscle weakness outweighs potential pain relief every time.
No pill works in a vacuum. Before someone starts Flupirtine, full medical histories matter, honest conversations about liver disease history need to happen, and patients should get practical explanations about what to watch for—jaundice, dark urine, new fatigue, not just vague “side effects.” Better tracking, including routine bloodwork, could catch problems early, but prevention trumps reaction. We see safer options for pain management and more doctors checking pharmacy records for drug interactions. In truth, it might be time to push for research into non-drug pain strategies and other medicines less likely to pile health problems on people looking for relief in the first place.
Many people deal with pain that doesn’t fade with typical over-the-counter options. Flupirtine maleate comes up as a non-opioid painkiller, especially in places where stronger solutions bring more risk than benefit—think chronic pain like muscle aches or nerve pain. You might wonder whether it plays nicely with other medication you take.
Doctors and patients alike juggle medicine cabinets stacked with more than one prescription. For example, anyone dealing with persistent pain may also have high blood pressure, diabetes, or depression. Each medication interacts with your body’s chemical processes. Flupirtine works by targeting brain pathways that block pain, not by suppressing inflammation. That sounds simple, but drugs rarely work in isolation inside us.
Combining medications without guidance can spark unexpected problems. Flupirtine, for instance, impacts liver enzymes that handle many other drugs. If paired with another medicine that stresses the liver, such as paracetamol or some antibiotics, risks like liver damage start to climb. Regulatory agencies in Europe pulled flupirtine off shelves after too many reports of liver injuries. So, anyone with existing liver issues should keep far away, especially if taking other medications that affect the same organ.
Mixing flupirtine with sedatives, alcohol, or medicines that slow the nervous system can lead to trouble. Flupirtine may intensify the effects of sedating drugs, making you groggy or affecting your ability to focus and react. Drivers, machine operators, or anyone needing to stay alert need straight talk about this risk.
Certain antidepressants, anticonvulsants, or muscle relaxants also affect the brain’s signaling, sometimes working alongside or against flupirtine in unpredictable ways. Stories of patients experiencing mood swings or changes in alertness after taking flupirtine with these drugs aren’t rare. In my own work with patients managing chronic pain, having a frank conversation about everything someone takes—down to that nightly glass of wine—often brings surprises that could have ended poorly if overlooked.
We all want comfort, but safety matters. People should tell their doctor or pharmacist about every medication, supplement, or herbal remedy in use. Bring the bottles to appointments if memory fails. Digital records help if you use one pharmacy, but sharing verbally gives a full picture.
Doctors must keep up with new research. Recently, experts warned that even short-term flupirtine use can cause harm if combined with specific drugs or in those with certain pre-existing conditions. I encourage regular blood tests while taking flupirtine, so warning signs don’t go missed. Pharmacists play a key role, double-checking new prescriptions against existing ones and catching red flags.
Everyone deserves treatment that makes life easier, not riskier. Flupirtine maleate might help some pain, but the price for letting drug interactions slip through isn’t worth it. Open, honest communication—backed by science, real data, and careful monitoring—avoids tragic outcomes.
| Names | |
| Preferred IUPAC name | N-(2-amino-6-oxo-1,6-dihydro-3-pyridinyl)-N-(4-fluorobenzyl)carbamate maleate |
| Other names |
Katadolon Metanor Trancolong Flupigen Flupirtin Vendal |
| Pronunciation | /fluːˈpɪrtiːn məˈleɪət/ |
| Identifiers | |
| CAS Number | 75507-68-5 |
| Beilstein Reference | 1310551 |
| ChEBI | CHEBI:38631 |
| ChEMBL | CHEMBL2104510 |
| ChemSpider | 21886673 |
| DrugBank | DB00397 |
| ECHA InfoCard | 100.236.444 |
| EC Number | 620-286-8 |
| Gmelin Reference | 765399 |
| KEGG | D01394 |
| MeSH | D000077207 |
| PubChem CID | 6918304 |
| RTECS number | YQ7080000 |
| UNII | 92RC8J60JO |
| UN number | UN3077 |
| Properties | |
| Chemical formula | C15H17FN4O•C4H4O4 |
| Molar mass | 506.06 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.6 g/cm3 |
| Solubility in water | Soluble in water |
| log P | 3.6 |
| Acidity (pKa) | 4.28 |
| Basicity (pKb) | 9.29 |
| Magnetic susceptibility (χ) | -53.5e-6 cm³/mol |
| Refractive index (nD) | 1.652 |
| Dipole moment | 2.84 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 365.2 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | No published data |
| Pharmacology | |
| ATC code | N02BX07 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. May cause drowsiness or dizziness. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHSA |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | Keep container tightly closed. Keep container in a cool, well-ventilated area. Keep away from sources of ignition. Avoid contact with skin and eyes. Avoid inhalation of dust or vapors. Use personal protective equipment as required. |
| Flash point | 130.5 °C |
| Autoignition temperature | 250°C |
| Lethal dose or concentration | LD₅₀ (oral, rat): 447 mg/kg |
| LD50 (median dose) | LD50 (median dose): Rat oral 523.1 mg/kg |
| NIOSH | SAF3984500 |
| PEL (Permissible) | PEL: Not Established |
| REL (Recommended) | 160 mg daily |
| IDLH (Immediate danger) | Not listed |
| Related compounds | |
| Related compounds |
Eflornithine Retigabine Tiropramide Carbamazepine Gabapentin |
